NCT06344052View on ClinicalTrials.gov

To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

March 30, 2029

Conditions
Basal Cell Carcinoma
Interventions
DRUG

SP-002

SP-002 is a replication deficient adenovirus-5 encoding human interferon gamma (IFNγ), designed for intra-tumoral administration

DRUG

Vismodegib

The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.

Trial Locations (10)

14564

RECRUITING

Research Site, Rochester

20850

RECRUITING

Research Site, Rockville

33065

RECRUITING

Research Site, Coral Springs

33157

RECRUITING

Research Site, Cutler Bay

33321

RECRUITING

Research Site, Boca Raton

64064

RECRUITING

Research Site, Lee's Summit

75601

RECRUITING

Research Site, Longview

77346

RECRUITING

Research Site, Humble

78613

RECRUITING

Research Site, Cedar Park

85006

RECRUITING

Research Site, Phoenix

All Listed Sponsors
lead

Stamford Pharmaceuticals, Inc.

INDUSTRY